about
Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay.The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET.Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.Novel agents in CNS myeloma treatment.Therapeutic advancements in multiple myeloma.13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.Second Generation Proteasome Inhibitors in Multiple Myeloma.Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials.Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.IgM myeloma: A multicenter retrospective study of 134 patients.Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma.Central nervous system multiple myeloma.Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma.Predicting the clinical course of Hodgkin lymphoma.Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection.A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2.Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.Hyperlipidemia in a myeloma patient after bortezomib treatment.Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.Bortezomib and restoration of chemosensitivity.Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
P50
Q31157227-C831AF79-C3A6-4852-8C0E-5B08874EF753Q33268051-EB7CBB6F-81A2-4918-AD04-882BB30D6AD5Q33384298-9EF34603-9E4F-4571-9191-17A7E90DA8DDQ33411708-47C5D3E5-A115-400B-897A-7DE05C5C8CB4Q33885555-7253F669-9B7D-408A-BFC7-ED5961EC4C48Q36091892-6F6C9AD3-FBA3-4B34-9F73-D83BA68D22F4Q37623386-FF7EAE0C-0D2E-43B7-AFEE-2FD00D4A85D9Q37804592-3943558C-A1B8-4772-AC43-4F019203D6E8Q38241035-97B97D17-5C23-4E23-B096-82F7A4813E7DQ38252583-D3802D44-0A2F-4E8F-B593-01B8AB0F3F00Q38491230-607BEBB4-8BF1-470A-8ED5-272FFDC44792Q38945876-94F674E7-0789-42A7-AFD4-91498C71CFCEQ38970829-F2D68DE5-63CA-4C6F-8CD2-E66721CABABDQ39046123-E17D6F39-5ABC-4178-B37D-02D6D1F8EF09Q39705915-03570AA7-60A3-4A1B-BE26-89D0768787EEQ40149390-30AA340B-BC28-4D23-A3A7-6F50A711F1A4Q40255441-09B9108B-5C59-4B24-93D7-C355217475FAQ40291554-F6F60557-4C1B-4A40-84B3-D1011BC186C7Q40561960-4B4BA5FA-4478-4F7A-BB1F-D091DD2E7037Q40607052-D7183A4B-439A-49D1-B4B2-BEE132FBD8DDQ40963301-A7803C5E-CFD8-4774-84EF-1002B3D7372CQ40993541-E6E7A007-E9EF-42AD-BE02-0DE5DAC54594Q42011392-9CC376BD-85D9-44A7-8847-20E383F93439Q42153319-08E47477-E883-46F8-B0A7-0A0A781A8A91Q42940915-E02143B7-0ABB-4114-8055-7ABC2C869CB5Q42979922-8A65313B-2396-45B6-85FF-AF737C2AD1BCQ42981360-29A731AA-C723-4300-8C24-F63EE66D3605Q43014597-4C57B331-9B88-4D29-A731-6F5F0B754096Q43062700-9C17BBFF-2A7B-4EB2-B071-15C4C789AC74Q43110361-A475AB12-0431-479A-B23B-8AD454CE0C90Q43119802-13423939-9D43-4217-A8AA-D4BC4075EB9DQ43132808-E82889CB-EC4B-435A-847E-688909E22053Q43146146-851E9173-385A-4FEE-BF23-A1176D071369Q43251926-480C3E2D-1985-476C-BFC8-BA34F2610042Q43252715-07566CB8-0137-4E2E-A05E-BEB2D25F934DQ43718924-16E7F0FC-80D1-4550-9412-B01B57AD3419Q43863797-DE0C66AB-D81B-4D17-A041-0838B69B884BQ44569938-DB004595-AB41-469A-8E9A-46637710912EQ44733664-CFAE260F-FC99-47D9-A51D-DC646266BC44Q44735593-F2C7D4FD-DE02-4FB8-BE7C-1397C45C5AF3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessandro Gozzetti
@ast
Alessandro Gozzetti
@en
Alessandro Gozzetti
@es
type
label
Alessandro Gozzetti
@ast
Alessandro Gozzetti
@en
Alessandro Gozzetti
@es
prefLabel
Alessandro Gozzetti
@ast
Alessandro Gozzetti
@en
Alessandro Gozzetti
@es
P1053
D-9055-2014
P106
P1153
6701815961
P21
P31
P3829
P496
0000-0003-0769-6891